Drugs / GSK208141
last change Jul 2007 re-read 2 minutes ago

GSK208141

also known as gD2t

Vaccine

Developed for
herpes simplex infectious disease
Investigated by
GlaxoSmithKline

Trials 7 · a red edge is where a trial was stopped

199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00698893 May → Jul 1992 herpes simplex infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00698490 Aug 1995 → Jan 1997 GlaxoSmithKline Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00697567 Sep 1992 → Dec 1997 GlaxoSmithKline Completed No outcome recorded
Phase 34 trials
Phase 3 NCT00224484 Apr 2004 → Jul 2007 herpes simplex infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00224471 Dec 2003 → Sep 2005 herpes simplex infectious disease GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00698568 Oct 1996 → Apr 1999 GlaxoSmithKline Completed No outcome recorded
Phase 3 NCT00699764 Mar 1996 → Oct 1999 herpes simplex infectious disease GlaxoSmithKline Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as GSK 208141 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00698490
6

NCT00699764

NCT00224471

NCT00698893

NCT00697567

NCT00224484

NCT00698568

Known as gD2t “Herpes Simplex Candidate Vaccine (gD2t)” NCT00698568
1

“Herpes Simplex Candidate Vaccine (gD2t)” NCT00699764

Modality Vaccine “candidate vaccineNCT00224471
Route Intramuscular “3 IM doses” NCT00224471